Clare L. Scott, MBBS, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, outlines the latest improvements in the treatment of cervical cancer. The INTERLACE study (NCT01566240) saw induction chemotherapy (CT) improve outcomes of women who would then receive standard treatment, increasing overall survival. The benefit is that this can be implemented now, as it does not require further drug approval. The A18 study (NCT04221945) tested pembrolizumab with CT, supporting the long-standing KEYNOTE 826 study’s (NCT03635567) hypothesis by improving both progression-free and overall survival. Studies are trialling tisotumab vedotin (TV) which has been found to reduce the risk of death in second-line cervical cancer, with outstanding statistics. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
